TScan Therapeutics, Inc. announced updated results from its ALLOHA Phase 1 trial, showing favorable relapse-free survival and overall survival in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation. TSC-101 was well-tolerated, with 100% of treated patients remaining relapse-free at two years, compared to 25% in the control arm. A virtual KOL event featuring Dr. Ran Reshef will discuss the data and market potential for TSC-101, which has shown promising results in addressing the unmet need for curative treatments in AML and MDS patients. The FDA has agreed to the pivotal study design for TSC-101.

Read more at GlobeNewswire: TScan Therapeutics Announces Positive Updated Data from the